Changes to the CalOptima Approved Drug List

Every 3 months, CalOptima’s Pharmacy and Therapeutics (P&T) Committee may change medications on the Approved Drug List. This committee includes doctors and pharmacists, and they decide which medications are placed on the list.

You can read and review the Approved Drug List on CalOptima’s website at [https://www.caloptima.org/Home/Members/Medi-Cal.aspx](https://www.caloptima.org/Home/Members/Medi-Cal.aspx). The Approved Drug List is revised every 3 months. Please talk with your doctor about any changes to the Approved Drug List that may affect you.

Changes to the Approved Drug List from the 5/16/2019 P&T Meeting

Requires a Step Therapy or Contingent Therapy Restriction Starting 7/1/2019:

- Glimepiride (Amaryl)
- Dimenhydrinate (Dramamine, Driminate)

Requires a Prior Authorization Starting 7/1/2019:

- Avatrombopag (Revcovi)
- Amifampridine Phosphate (Firdapse)
- Erdafitinib (Balversa)
- Caplacizumab-YHDP (Cablivi)
- Tagraxofusp-erzs (Elzonris)
- Trastuzumab-hyaluronidase-OYSK (Herceptin Hylecta)
- Dolutegravir sodium/lamivudine (Dovato)
- Stiripentol (Diacomit)
- Esketamine (Spravato)